MDST Medicsight

RNS Number:1856H
Medicsight Plc
07 November 2007


Press Release                                                   7 November 2007




                                 Medicsight PLC

                        ("Medicsight" or "the Company")

                    Third Quarter Summary Trading Statement



Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, is pleased to announce summary Interim Results for the
quarter ended 30 September 2007.



Highlights


*    First commercial bookings
*    Regulatory approval granted in Australia for ColonCADTM



David Sumner, Chief Executive of Medicsight PLC, commented: "I am delighted to
announce that the Company's first revenue bookings have taken place this
quarter. This is an important commercial milestone for the Company and paves the
way for anticipated profitability in 2008. In addition our contract pipeline
also continues to grow and regulatory approvals continue as planned, including
the initial regulatory approval for our ColonCADTM product in Australia. In
relation to future product delivery, the development group is making good
progress and is on schedule to deliver against the revised product roadmap.



"The most important news item however for this quarter is the recent
announcement from The American College of Radiology Imaging Network (ACRIN), a
national cancer research organization sponsored and funded by the US National
Cancer Institute, in relation to the ACRIN 6664 study. This large multi-centre
study demonstrates that CT Colonography is as sensitive as Optical Colonoscopy
when screening for colorectal polyps with a diameter in excess of 1 cm. We
believe that this landmark clinical study now provides the data required to
enable CT Colonography to be included in the major screening guidelines for
colorectal cancer in the USA. This also makes the reimbursement landscape look
very encouraging for CT Colonography in the world's largest medical imaging
market."



Summary Financial Data



For the three months to 30 September 2007 net revenue to external customers was
#6,000 (2006: nil) with an operating loss before interest and tax of #1,883,000
(2006: #551,000). For the nine months to 30 September 2007 net revenue to
external customers was #6,000 (2006: nil) with an operating loss before interest
and tax of #5,449,000 (2006: #3,706,000). Reflecting the funds raised in the
initial public offering in June this year, the Group's total assets at 30
September 2007 were #27,412,000 (30 September 2006: #1,169,000).



                                    - ENDS -



For further information:
Medicsight PLC                                             www.medicsight.com
David Sumner                                            Tel: +44 (0)20 7605 7950

Collins Stewart Europe Limited
Tim Mickley                                             Tel: +44 (0)20 7523 8350

Jonny Sloan                                             Tel: +44 (0)20 7523 8302





Media enquiries:
Abchurch                                                  www.abchurch-group.com
Ashley Tapp                                            Tel: +44 (0) 20 7398 7700
ashley.tapp@abchurch-group.com
Stephanie Cuthbert                                     Tel: +44 (0) 20 7398 7700
stephanie.cuthbert@abchurch-group.com



Notes to editors

Medicsight PLC is a UK-Headquartered, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's computer-aided detection (CAD) software has been validated
using one of the world's largest and most population diverse databases of
verified patient CT scan data. Medicsight's ColonCADTM and LungCADTM software
products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.



About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.



About Medicsight's CAD software

Medicsight's ColonCADTM and LungCADTM software use an advanced CAD algorithm to
analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.



Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.



Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IMSOKOKQKBDDNDK

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024